Amylyx Pharmaceuticals, Inc. (AMLX)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$27.78−0.04%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $3.5B
- 52-week range
- $10.83 – $41.14
- 52-week change
- +118.99%
- EPS (trailing)
- −$1.41
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$145M
- Diluted EPS
- −$1.53
- Free cash flow
- −$123M
From the company’s annual report on SEC EDGAR.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 136 employees · amylyx.com